Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease ...

Study reveals one-third of mantle cell lymphoma patients in a study at leading cancer centers experienced disease progression ...

Emilie Aschenbrenner, PharmD, BCOP, highlights how measurable residual disease (MRD) testing can support value-based care in ...

A recent study aimed to assess evidence on the safety and complications of preoperative glucagon-like peptide-1 (GLP-1) ...

Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation ...

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

Shared decision-making helps dermatologists align treatment plans with patient needs, improving adherence and outcomes.

A national survey finds patients want personal contact after positive cancer results, with psychosocial fears outweighing cost and transportation concerns.

Despite its potential, incorporating new treatments like T-DXd into a first-line setting faces several barriers, explains Michael Hassett, MD, MPH, chief quality officer at Dana-Farber Cancer ...